JPRN-jRCT2080220530未知1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years to 75 Years
- •Genders Eligible for Study: Both
- •Accepts Healthy Volunteers: No
- •Inclusion Criteria:
- •-Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments.
- •-Patients who usually have mild symptoms capable of walking and light and sedentary work.
- •-Patients who can stay in hospital at least during 4 weeks.
排除标准
- •-Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.
- •-Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function.
- •-Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.
研究者
相似试验
未知
1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignanciesadvanced solid malignanciesJPRN-jRCT2080220617AstraZeneca
未知
1 期
A Phase 1, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid MalignanciesJPRN-jRCT2080220802AstraZeneca45
未知
1 期
A Phase I, Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080220492AstraZeneca
尚未招募
2 期
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers (BET115521)NUT Midline Carcinoma and other solid tumors10027655NL-OMON43804GlaxoSmithKline10
Unknown
1 期
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿G-ZEBOV) Ebola Virus Vaccine Candidate.EbolaPACTR201411000919191niversitaetsklinikum Tuebingen60